FMR LLC - 09 Nov 2026 Form 4 Insider Report for Avalyn Pharma Inc. (AVLN)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
12 Nov 2026, 11:35:59 UTC
Prior SEC filing
24 Jul 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Stephanie J. Brown, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson
Filing notes and source

Key filing fact

FMR LLC filed Form 4 for Avalyn Pharma Inc. (AVLN) on 12 Nov 2026.

Key facts

  • This page summarizes FMR LLC's Form 4 filing for Avalyn Pharma Inc. (AVLN).
  • 4 reported transactions and 0 derivative rows are listed below.
  • Accepted by SEC: 12 Nov 2026, 11:35.

Change

  • Previous filing in this sequence was filed on 24 Jul 2026.
  • Current net transaction value: -$6,701,004.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0000315066 Primary reporting owner

FMR LLC

Relationship
Other*, 10%+ Owner
Address
245 SUMMER STREET, BOSTON
Signature
/s/ Stephanie J. Brown, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson
Signature date
12 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AVLN transaction

Common Stock

Sale

Transaction value
-$5,046,589
Shares
-173,661
Change %
-7.6%
Price
$29.06
Shares after
2,110,874
Date
09 Nov 2026
Ownership
F-Prime Capital Partners Healthcare Fund V LP
Footnotes
F1
AVLN transaction

Common Stock

Sale

Transaction value
-$39,835
Shares
-1,339
Change %
-0.06%
Price
$29.75
Shares after
2,109,535
Date
09 Nov 2026
Ownership
F-Prime Capital Partners Healthcare Fund V LP
Footnotes
F2
AVLN transaction

Common Stock

Sale

Transaction value
-$164,501
Shares
-5,565
Change %
-0.26%
Price
$29.56
Shares after
2,103,970
Date
10 Nov 2026
Ownership
F-Prime Capital Partners Healthcare Fund V LP
Footnotes
F3
AVLN transaction

Common Stock

Sale

Transaction value
-$1,450,079
Shares
-47,889
Change %
-2.3%
Price
$30.28
Shares after
2,056,081
Date
10 Nov 2026
Ownership
F-Prime Capital Partners Healthcare Fund V LP
Footnotes
F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $28.65 to $29.64. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.

Footnote F2

The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $29.68 to $29.83. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.

Footnote F3

The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $28.82 to $29.81. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.

Footnote F4

The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $29.82 to $30.62. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.

SEC remarks

Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: The general partner of F-Prime Capital Partners Healthcare Fund V LP is F-Prime Capital Partners Healthcare Advisors Fund V LP (FPCPHA). FPCPHA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .